Important Research Presented at 2011 Breast Cancer Symposium

FOR IMMEDIATE RELEASE
September 8, 2011
Contact: 

Susie Tappouni
571-483-1355
susie.tappouni@asco.org

ALEXANDRIA, Va. – Co-sponsors of the 2011 Breast Cancer Symposium announced seven additional studies of note on breast cancer treatment, side effects, recurrence and survival rates, and survivorship. The findings will be presented during this year’s Symposium, which takes place September 8-10 in San Francisco.

Abstract # 82
Impact of chemotherapy timing on local-regional failures in patients with breast cancer undergoing breast-conserving therapy


Oral Abstract Session A
Yerba Buena Ballroom, Salon 8
Thursday September 8
1:30-1:40 PM PT


“Traditionally, surgery has been performed prior to chemotherapy in women with large breast cancers. This study demonstrated that in women undergoing chemotherapy first, the risk of local recurrence was the same as in women undergoing surgery first. Administering chemotherapy first may allow for ‘downstaging’ or a significant decrease in the size of the cancer prior to surgery. There is no adverse effect on recurrence rates. While this study did not address cosmesis, decreasing the size of the tumor prior to surgery may allow for a more cosmetically acceptable lumpectomy to be performed."
– Deanna Attai, MD
Member, 2011 Breast Cancer Symposium News Planning Team
Center for Breast Care, Inc.


Abstract #83
Outcomes by breast cancer subtype in patients treated with accelerated partial breast irradiation


Oral Abstract Session A
Yerba Buena Ballroom, Salon 8 Thursday, September 8
1:50-2:00 PM PT


Abstract #84
Accelerated partial breast irradiation using brachytherapy (APBIb) for breast cancer (bca): Predictors of use and guideline concordance


Oral Abstract Session A
Yerba Buena Ballroom, Salon 8
Thursday, September 8
2:00-2:10 PM PT


"These two abstracts on partial breast radiotherapy provide important insight into this relatively new technique. While awaiting the completion and publication of the randomized trial, the group at Beaumont – who have long been leaders in this field – have shown that this approach is equally appropriate in various subsets of breast cancer patients. The Harvard group, who helped direct ASTRO's guidelines on the usage of this technique, demonstrate that the adoption of this approach varies widely by geographic region, and that adherence to the guidelines has not been as hoped. Partial breast radiation will continue to be offered as an alternative therapy/option approach to selected low-risk groups. Published data now show it to be equivalent to more protracted radiation schedules.”
– H. Joseph Barthold, MD
Member, 2011 Breast Cancer Symposium News Planning Team
Commonwealth Hematology Oncology, Massachusetts


Abstract #147
Needs and preferences of breast cancer survivors: A cross-sectional survey


General Session V: Survivorship
Yerba Buena Ballroom, Salon 8
Friday, September 9
10:00-10:10 AM PT


“While 50% of patients in this study were stage 0-1, a significant proportion continued to report worry (52%) in the past week. Interestingly, patients felt that screening for non-breast related issues, such as osteoporosis and colorectal cancer, were more important than support groups and social work services. These findings are intriguing and should spur discussion regarding the ongoing needs of breast cancer survivors and how physicians can best address their diverse needs.”
– Anees B. Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)
Member, 2011 Breast Cancer Symposium News Planning Team
Director, The Breast Center – Smilow Cancer Hospital at Yale-New Haven
Associate Professor, Department of Surgery, Yale School of Medicine


Abstract #2
Prediction of late recurrences by breast cancer index in the NCIC CTG MA.17 cohort


Oral Abstract Session A
Yerba Buena Ballroom, Salon 8
Thursday, September 8
1:00-1:10 PM PT


“Despite the judicious use of adjuvant systemic chemotherapy and antiestrogen therapy, many patients will relapse beyond 5 and 10 years after treatment and die of advanced breast cancer. The authors report a case-control study examining a novel molecular predictor of late recurrences in estrogen receptor positive breast cancer following five years of tamoxifen. Confirmation of the prognostic utility of this could guide the selection of specific adjuvant strategies, agents, and treatment duration to reduce the risk of late recurrence.”
– Andrew D. Seidman, MD
Member, 2011 Breast Cancer Symposium News Planning Team
Attending Physician for the Breast Cancer Medicine Service,
Memorial Sloan-Kettering Cancer Center


Abstract #270
Relationship between taxane-induced neuropathy and clinical outcomes after adjuvant chemotherapy


Oral Abstract Session B
Yerba Buena Ballroom, Salon 8
Friday, September 9
2:30-2:40 PM PT


“As components of adjuvant chemotherapy, taxanes improve relapse-free and overall survival. Their use can be limited by peripheral neuropathy. Prior work has demonstrated the potential for single nucleotide polymorphisms (SNPs) to predict for taxane neurotoxicity (Schneider ASCO 2011, Abstract 1000). The current analysis, derived from ECOG1199 (Sparano J et al. NEJM) provides reassurance that taxane neuropathy is not linked to taxane benefit.”
– Andrew D. Seidman, MD
Member, 2011 Breast Cancer Symposium News Planning Team
Attending Physician for the Breast Cancer Medicine Service,
Memorial Sloan-Kettering Cancer Center


Abstract #32
Male breast carcinoma in United States: Survival rate and determinants of prognosis


General Poster Session A
Yerba Buena Ballroom, Salon 8
Poster Board C3
Thursday, September 8
11:30 AM-1:00 PM PT


“While the study itself has some limitations, the authors confirm what has been shown historically. Breast cancer in men occurs later in life, is frequently associated with a delay in diagnosis, and is commonly associated with lymph node involvement. Although breast cancer is rare in men, these findings demonstrate that it is critically important to continue to raise awareness about the occurrence of breast cancer in men.”
– Gail S. Lebovic, MA, MD, FACS
Member, 2011 Breast Cancer Symposium News Planning Team
Past President, American Society of Breast Disease

###

Relevant Links on ASCO’s Patient Website, Cancer.Net:

2011 Breast Cancer Symposium News Planning Team
Gail Lebovic, MD, American Society of Breast Disease; Deanna J. Attai, MD, FACS, American Society of Breast Surgeons; Andrew D. Seidman, MD, American Society of Clinical Oncology (ASCO); H. Joseph Barthold, MD, American Society for Radiation Oncology (ASTRO); Anees B. Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C), MD, Society of Surgical Oncology.

ATTRIBUTION TO THE 2011 BREAST CANCER SYMPOSIUM IS REQUESTED IN ALL COVERAGE.